Point of Care Diagnostics Market

The point-of-care diagnostics market is projected to reach USD 31.46 billion by 2031, up from USD 20.63 billion in 2026, growing at a CAGR of 8.8%.

Point-of-care (POC) diagnostics have become an essential part of modern healthcare, enabling rapid diagnosis and clinical decision-making at or near the patient. The market includes blood glucose monitoring, infectious disease testing, cardiac biomarkers, blood gas and electrolyte analyzers, coagulation testing, HbA1c, urinalysis, pregnancy and fertility tests, molecular diagnostics, and multiplex respiratory panels. The rising prevalence of chronic and infectious diseases, the increasing demand for decentralized healthcare, and the expanding adoption across hospitals, physician offices, pharmacies, retail clinics, ambulatory care centers, and home healthcare are driving market growth. Recent advancements in molecular POC platforms, AI-enabled data connectivity, biosensors, and CLIA-waived testing have improved diagnostic accuracy, turnaround time, and accessibility. Supported by growing investments in early diagnosis, remote healthcare, and personalized medicine, point-of-care diagnostics continue to play a pivotal role in improving patient outcomes and advancing global healthcare delivery.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US).

Abbott Laboratories (US)

Abbott Laboratories' leadership in the point-of-care diagnostics market is driven by its broad portfolio of rapid diagnostic solutions and strong presence across decentralized healthcare settings. The company offers a comprehensive range of point-of-care products, including blood glucose monitoring systems, i-STAT handheld blood analyzers, cardiac biomarker tests, infectious disease assays, and rapid diagnostic tests used in hospitals, emergency departments, physicians' offices, retail clinics, and home care. Abbott benefits from an extensive global distribution network, continuous investment in innovation, and strong brand recognition, enabling rapid adoption across both developed and emerging markets. Its focus on expanding connected diagnostics and improving clinical workflow reinforces its position as the global market leader in point-of-care diagnostics.

Danaher Corporation (US)

Danaher's position in the point-of-care diagnostics market is supported by its diversified diagnostics portfolio, which includes Beckman Colter Diagnostics, Radiometer, and Cepheid. The company provides blood gas and electrolyte analyzers, molecular point-of-care platforms, cardiac testing solutions, and critical care diagnostics designed for emergency departments, intensive care units (ICUs), laboratories, and near-patient settings. Its expertise in molecular diagnostics, automation, and digital connectivity, combined with a strong global commercial footprint, enables rapid and accurate clinical decision-making. Continuous investment in innovation and expansion of decentralized testing capabilities further strengthens Danaher's competitive position.

F. Hoffmann-La Roche Ltd. (Switzerland)

F. Hoffmann-La Roche Ltd. is a leading player in the point-of-care diagnostics market, supported by its extensive portfolio of near-patient testing solutions under Roche Diagnostics. The company offers blood glucose monitoring systems, coagulation testing, cardiac biomarker testing, infectious disease diagnostics, molecular point-of-care platforms, and immunoassay solutions for hospitals, physicians' offices, outpatient clinics, pharmacies, and home healthcare. Roche leverages its expertise in in vitro diagnostics, digital healthcare, and personalized medicine to deliver high-quality, rapid diagnostic results. Its strong global presence, continuous product innovation, and focus on integrated diagnostic ecosystems position the company as one of the foremost providers of point-of-care diagnostics worldwide.

Market Ranking

The point-of-care diagnostics market is moderately consolidated, with the leading players accounting for approximately 60–65% of the global market in 2025. Key market participants include Abbott Laboratories (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), and Werfen S.A. (Spain). These companies maintain their leadership through diversified product portfolios, continuous product innovation, strong regulatory capabilities, and extensive global distribution networks.

The market presents significant growth opportunities across North America, Europe, and Asia-Pacific, particularly in China, India, Japan, and South Korea, driven by expanding healthcare infrastructure, increasing adoption of decentralized diagnostics, growing healthcare investments, and strategic expansion of manufacturing and commercial operations.
The rising prevalence of diabetes, cardiovascular diseases, infectious diseases, and respiratory disorders, coupled with the growing demand for rapid, decentralized testing, is driving adoption across clinical laboratories, hospitals, ambulatory care facilities, physicians' offices, pharmacies, retail clinics, and home healthcare settings.

Technological advancements in molecular diagnostics, immunoassays, biochemistry analyzers, microfluidics, and portable testing platforms are improving diagnostic speed, accuracy, and accessibility. Companies are increasingly focusing on multiplex testing, digital connectivity, and compact point-of-care systems to strengthen their competitive positioning and support the growing shift toward decentralized healthcare.

Related Reports:

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]